Today, BioSpace, a well-known media website in the biopharmaceutical industry, announced the selection of the "NextGen Bio 'Class of 2023'" — the new generation of biotech innovators for 2023.BioSpace evaluated emerging companies that completed Series A financing between September 2020 and September 2021. Through a comprehensive assessment of the companies' financing, partnerships, R&D pipelines, growth potential, and innovation, 24 life science startups were selected for the list.Many of these emerging companies have already had a significant impact on the industry. Let us look forward to their continued contributions to the development of biopharmaceuticals, bringing more medical breakthroughs to benefit more patients in the future!
1. Neumora Therapeutics
Neumora focuses on precision medicine research for brain diseases. Neumora's proprietaryThe Data Biopsy Signatures platform integrates multi-layered data, including genomics, imaging, electroencephalography (EEG), and clinical symptoms, to explore the multiple drivers and precise phenotypes of brain diseases, thereby matching targeted therapies.Neumora and Amgen Reach $500 Million Strategic Collaboration in Brain Neuroscience Field in October 2022Completed $112 Million Series B Financing。
Neumora currently has numerous preclinical and clinical-stage programs targeting many clinically validated or innovative targets for the treatment of various neuropsychiatric and neurodegenerative disorders. In October last year, Neumora completed patient recruitment for the phase 2a clinical trial of its lead program NMRA-140. NMRA-140 is a research κ-opioid receptor antagonist for the treatment of depression. Additionally, the company has ongoing clinical-stage programs including NMRA-511, a vasopressin 1a receptor antagonist for neuropsychiatric disorders, and NMRA-266, an M4 muscarinic receptor positive allosteric modulator that will enter phase 1 clinical trials in 2023. Neumora also has several early-stage development programs with "first-in-class" potential, focusing on Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
2. Altos Labs
Altos Labs was founded to uncover the mysteries of cellular rejuvenation, restore cell health, and enhance their ability to resist disease. To achieve this ambitious goal,The company has attracted four Nobel laureates and top scientists from various related fields around the world to join. Meanwhile, at the time of its establishment,Secured $3 billion in investment。According to the industry media STAT, this is the largest investment in the biotechnology field in history.
Altos focuses on unlocking the process of aging at the cellular level and potential reversal mechanisms, enhancing cellular resistance through diverse programming to optimize their resilience.Thereby promoting the development of drugs related to longevity and anti-aging.
3. Odyssey Therapeutics
Odyssey Therapeutics is a biotechnology company focused on the discovery, development and commercialization of next-generation immunomodulators and oncology drugs. Currently,Odyssey is building a discovery engine that combines artificial intelligence and machine learning for molecular design, a chemical platform containing a proprietary covalent library targeting multiple amino acids, molecular glues, and natural products, as well as a functional genomics platform for novel target discovery.
In December 2021, Odyssey Therapeutics announced the completion of a $218 million Series A financing round in less than a year.Completed $168 Million Series B FinancingThrough these funds, Odyssey is rapidly advancing its immunology and oncology programs, focusing on targets that have been validated but do not yet have approved solutions. The current pipeline includes eight announced small molecule and protein therapy projects.
4. Affini-T Therapeutics
Affini-T Therapeutics was co-founded by scientists from the Fred Hutchinson Cancer Center in the United States.Aiming to leverage synthetic biology and gene editing to target cancer driver mutations, developing a new generation of T-cell receptor (TCR) cell therapies.The company's R&D strategy is to target cancers driven by specific oncogene mutations (e.g.,KRASGene mutation-driven cancer), discovering specific TCRs already present in the human body.These TCRs can distinguish between KRAS mutants and wild-type KRAS, providing selectivity for TCR cell therapy.
Affini-T Therapeutics announced in March last yearCompleted $175 Million Financing。Affini-T's proprietary platform is designed to select and engineer the right immune cells to generate durable and coordinated immune responses. The company’s innovative synthetic biology switches can rewrite the rules of the tumor microenvironment by enhancing T-cell persistence, establishing sustained responses, and improving tumor infiltration to enhance T-cell functionality.The company's R&D pipeline includes targetedKRAS G12V andKRASG12D mutant, as well as candidate TCR cell therapies for p53 mutants. Investigational therapies targeting virus-driven cancers have entered the clinical development stage.
In June last year, Upstream Bio announcedCompleted $200 Million Series A Financing`, the funds will be used to advance the clinical development of its lead investigational therapy, UPB-101.`UPB-101 is a monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. TSLP is an epithelial cell cytokine that sits at the apex of multiple inflammatory cascades and may influence various allergic and inflammatory diseases, including asthma.Upstream Bio Obtains Development Rights for UPB-101 from Astellas, Which Has Completed Preclinical and Initial Clinical Phase Studies. Upstream Has Selected Asthma as the First Indication for UPB-101 and Plans to Explore Other Diseases Driven by TSLP-Mediated Inflammation.Capstan Therapeutics is a company focused on developing cell type-specific engineered cell therapies, with the potential to treat various diseases such as cancer, autoimmune disorders, blood-related conditions, and fibrosis.Its proprietary technology mainly consists of three components: a non-viral delivery system, cell type-specific targeting molecules, and disease-specific payload design.Capstan Therapeutics' proprietary targeted lipid nanoparticle (tLNP) technology can mediate cell type-specific uptake and, through the design and delivery of disease-related mRNA, achieve in vivo delivery of chimeric antigen receptors (CAR) to specific immune cells to eliminate diseased cells.Capstan Therapeutics prioritizes the development of projects that could bring transformative changes to clinical standard treatments. Examples include the development of a potential "first-in-class" in vivo CAR therapy deliverable via outpatient procedures to treat diseases currently lacking effective therapies, as well as advancing novel therapeutic approaches for certain monogenic blood disorders. Capstan achieved this milestone in September of last year.Completed $165 MillionThe seed round and Series A financing were participated in by the investment departments of major pharmaceutical companies such as Pfizer, Bayer, Eli Lilly, Bristol-Myers Squibb, and Novartis.
Alto Neuroscience is a startup in the field of precision psychiatry, focusing on developing targeted drugs to help patients with mental disorders recover more quickly.The company's precision psychiatry platform detects brain biomarkers by analyzing electroencephalographic activity, behavioral performance, wearable device data, genetics, and other factors to match the appropriate medication for each patient.Alto completed a $35 million Series B financing round in October last year, bringing the total amount of financing received by Alto to $75 million. The company's clinical-stage pipeline includes candidate drugs for the treatment of depression, post-traumatic stress disorder, and other mental health conditions.In December last year, Alto Neuroscience announced that its innovative drug combination targeting the cyclic adenosine monophosphate (cAMP) signaling pathway showed results in a Phase 1 human brain mechanism study.Achieve Positive Results。The company's ALTO-103 and ALTO-104 innovative combination therapies demonstrated significant pharmacodynamic effects compared to placebo in indicators related to patient response. These findings indicate that these candidate drugs possess pharmacological activity, supporting further evaluation in patients.
IDRx, Inc. in August last yearCompleted $122 Million Series A FinancingIDRx aims to develop highly selective, rationally designed drug combinations to overcome the limitations of current precision cancer therapies and help more patients achieve longer-lasting relief in the early stages of the disease.IDRx, Inc.'s strategy is to use combination therapy before cancer cells accumulate many mutations. This includes drugs that strongly target major cancer drivers and drugs that block cancer cell escape pathways.This strategy blocks the "escape route" of cancer cells from the start, offering the potential for more durable relief. IDRx's pipeline includes two small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, licensed from Merck KGaA and Blueprint Medicines, respectively. They are designed to inhibit key genetic drivers and resistance mutations in non-PDGFR-driven gastrointestinal stromal tumors (GIST). The first-in-human clinical trial for IDRX-42 has been initiated, and it has also received orphan drug designation from the U.S. FDA for the treatment of GIST.9. Intergalactic TherapeuticsIntergalactic Therapeutics Focuses on Developing Non-Viral Gene TherapiesIts breakthrough platform is based on two proprietary technologies: 1) Covalently Closed Circular DNA (C3DNA), which does not integrate into the host genome or cause adverse immune responses, and allows for the delivery of large genes; 2) An advanced system (COMET) that utilizes pulsed electric fields for localized gene therapy delivery.Intergalactic Therapeutics' covalently closed circular DNA (C3DNA) designed using synthetic biology can be taken up by cells and expressed. Produced through a cell-free manufacturing process, it contains no viral or bacterial sequences, thus avoiding recognition by the immune system. This allows C3DNA to function like an endogenous gene, enhancing the durability of gene expression and enabling repeated dosing.Intergalactic Therapeutics in October 2021Completed a $75 million Series A financing round。
Septerna was obtained in January 2022$100 Million Series A FinancingSepterna was launched by several scientists who have conducted pioneering research in GPCRs, in collaboration with the investment firm Third Rock Ventures.Dr. Robert Lefkowitz is one of the founders, and he was co-awarded the 2012 Nobel Prize in Chemistry for his contributions to the field of G protein-coupled receptors (GPCR).Septerna, Inc. is discovering and advancing a pipeline of novel small-molecule drugs targeting GPCRs across a wide range of disease areas.Septerna’s technology platform can reproduce the natural structure, function, and dynamics of GPCRs outside the cellular environment. This technology facilitates the rapid resolution of GPCR-ligand binding structures and accelerates structure-based drug design.Chroma's goal is to efficiently simulate epigenetic gene regulatory mechanisms for precise and long-lasting control of gene expression.Chroma's programmable epigenetic editor couples a DNA-binding domain with an epigenetic effector domain, where the DNA-binding domain specifically targets individual or multiple genes to be silenced or activated, and the effector domain is responsible for regulating DNA methylation patterns, controlling chromatin conformation, and activating or suppressing gene expression.This method does not require cutting DNA sequences or activating unpredictable DNA repair pathways, avoiding potential side effects caused by cutting DNA sequences.Chroma Medicine in November 2021Completed $125 Million Series A FinancingThe funds obtained from this financing will be used to support the development of the company's epigenetic gene editing technology platform.
Ceptur Therapeutics aims to utilize a technology called U1 adaptors to target and silence specific pre-mRNA.U1 Adaptor is a bivalent oligonucleotide, one end of which can bind to a precursor mRNA containing a specific sequence, and the other end binds to U1 small nuclear ribonucleoprotein (small nuclear ribonuclear protein, U1 snRNP).U1 snRNP is a widely present cellular mechanism that regulates transcription and splicing. It modulates gene expression at the pre-mRNA level, making this therapeutic approach potentially target otherwise difficult-to-drug targets.InNature BiotechnologyAn article published onThe off-target effects of U1 adaptors are limited, and no adverse effects on splicing have been observed. Moreover, the use of multiple U1 adaptors or the combination of U1 adaptors with siRNA can enhance the effect of gene silencing.Ceptur Therapeutics was established in January of last year.Completed a $75 million Series A financing roundThe funds obtained from this financing were used to advance its differentiated gene medicine R&D pipeline.
Clade Therapeutics was founded to overcome the current clinical limitations of cell therapy, unlocking the transformative potential of this increasingly important treatment modality by addressing persistence, patient compatibility, reproducibility, and scalability.Clade Therapeutics, Inc. in November 2021Completed an $87 million Series A financing round, to support the development of the company's proprietary platform.Its proprietary platform modifies allogeneic iPSCs to make them "invisible" to evade attacks from the host immune system, enabling immune-compatible cell transplantation after differentiation into therapeutic cells, thereby developing a new generation of off-the-shelf cell therapies.The company's early focus was on cancer.
Triana Biomedicines, Inc. was last AprilCompleted $110 Million Financing，with the goal of establishing a potential "best-in-class" scalable technology platform for the discovery and development of molecular glues.The goal of the TRIANA platform is to generate products that stabilize pre-existing interactions between two proteins or create new interactions, altering the fate or function of disease targets.Molecular glues may enable the development of "undruggable" targets highly relevant to diseases or targets not adequately addressed by traditional drug discovery methods.TRIANA's R&D strategy focuses on target-centric rational design and discovery of molecular glues.The company's innovative platform is capable of evaluating and prioritizing more than 600 known E3 ubiquitin ligases and their disease-related targets, while rapidly exploring a diverse chemical space for the discovery of molecular glue degraders.The company hopes to develop products with broad therapeutic applications through this approach.Code Bio aims to develop genetic medicines to treat and potentially cure severe and life-threatening genetic diseases.Code Bio leverages its novel synthetic DNA-based non-viral delivery platform, 3DNA, to overcome many of the inherent challenges associated with viral-based delivery methods, including immunogenicity, payload size and delivery limitations, inability to re-dose, and production complexity.According to the official website introduction,The design of the 3DNA platform enables this vector to achieve cell-specific targeting, delivery of large genetic payloads, and has the potential for repeated dosing.3DNA has been proven to deliver genes close to 10kb in size. By conjugating ligands that bind to specific tissue or cell surface receptors on DNA-based carriers, 3DNA vectors can selectively deliver gene therapeutics. The manufacturing of 3DNA vectors is simple and reproducible, enabling scalable production and storage.In February last year, Code Biotherapeutics, Inc. and TakedaReach a R&D AgreementUtilizing Code Bio's proprietary 3DNA targeted non-viral gene drug delivery platform to design and develop gene therapies for rare disease indications targeting the liver and central nervous system.
Satellite Bio is dedicated to leveraging bioengineering to create tissue therapeutics, repairing, restoring, or replacing the functions of critical organs or tissues.Satellite Bio's proprietary technology platform can implant different types of endocrine and paracrine cells (including primary cells, cells differentiated from induced pluripotent stem cells, or engineered cells) into a matrix to generate transplants that can be transplanted into patients.After being surgically transplanted into patients, they have the potential to integrate into the transplant environment, fully exert their functions, and repair, restore, or replace dysfunctional tissues or organs. Satellite Bio was established in April last year.Total $110 Million CompletedSeed Round and Series A Financing.
Ambagon Therapeutics aims to stabilize the structure of intrinsically disordered proteins by developing molecular glues, targeting protein targets traditionally considered "undruggable."Adaptor proteins known as 14-3-3 can bind to many proteins containing disordered regions, including the Raf protein kinase that drives cancer, FOXO transcription proteins, the p53 tumor suppressor protein, and more.Ambagon Therapeutics applies a deep understanding of 14-3-3 proteins and a proprietary set of drug discovery tools to create molecular glues that stabilize the complex structures formed by 14-3-3 and its interacting proteins.By stabilizing natural protein interactions, these molecular glues can amplify the outcomes of protein interactions, such as inhibiting disease-driving protein activity, enhancing or stabilizing protein activity, and promoting the degradation of disease-driving proteins.Ambagon Therapeutics was established in January last year.Completed an $85 million Series A financing round, to improve its drug discovery platform and advance its molecular glue pipeline. Currently, the company's R&D pipeline primarily focuses on oncology, with five ongoing research projects.Epic Bio, founded by renowned bioengineer Dr. Stanley Qi, a protégé of CRISPR pioneer Professor Jennifer Doudna, is dedicated to developing therapies for in vivo regulation of gene expression based on compact Cas proteins.Epic Bio's technology platform is called the Gene Expression Modulation System (GEMS).It can precisely regulate the level of gene expression.This system includes one of the largest regulatory sub-libraries currently available, along with advanced functional genomics and computational genomics capabilities.Highly target gene-specific guide RNAs (gRNAs) can be rapidly designed.Epic Bio in July last yearCompleted a $55 million Series A financing round, to support the company's preclinical R&D projects targeting five currently unresolved indications, including heterozygous familial hypercholesterolemia (HeFH) and alpha-1 antitrypsin deficiency (A1AD).Ansa Biotechnologies raised $68 million in Series A funding in April last year.Aimed at developing the next-generation DNA synthesis enzyme platform.The current standard method for DNA synthesis in the industry is the phosphoramidite approach, which not only involves the use of many hazardous chemicals but also has the potential to damage molecules or result in a higher rate of synthesis errors.Ansa Biotechnologies' enzyme-based innovative DNA synthesis platform has the potential for faster, longer, and more accurate DNA synthesis.
Totus Medicines raised $40 million in Series A funding in December 2021, with the goal of leveraging its unique drug discovery platform to make every human disease treatable.The Totus platform is based on a large-scale and comprehensive covalent chemistry library, combined with its ultra-high-throughput cell screening analysis technology and large-scale artificial intelligence/machine learning for drug design.Totus Medicines' lead drug candidate currently in the preclinical stage is the PI3Kα inhibitor TOS-358, with PI3Kα being an oncogene present in many tumor tissues.
The integration of spatial genomics is a rapidly developing field that may contribute to significant breakthroughs in precision medicine, biotechnology, and molecular biology. Spatial Genomics, Inc. secured $56 million in Series A funding in February last year.Aiming to identify molecules and their locations within single cells by combining intron sequential fluorescence in situ hybridization (seqFISH) with molecular barcoding, Spatial's powerful platform may represent a significant step forward in the field of integrated spatial genomics analysis.
Seismic Therapeutic in February last yearCompleted $101 Million Series A Financing。Seismic Therapeutic's unique IMPACT technology platform systematically integrates machine learning, structural biology, protein engineering, and translational immunology, enabling the development and optimization of novel biologics with significantly improved efficiency and scale compared to traditional therapeutic drug discovery.Through this new approach, the company is accelerating the development of a pipeline of biologics targeting dysfunctions in the adaptive immune system to treat autoimmune diseases. The funds raised from Series A financing will further advance Seismic Therapeutic's first two lead drug programs, targeting Ig (immunoglobulin)-mediated and cell-mediated autoimmune diseases, respectively.
64x Bio, Inc.The goal is to use high-throughput screening to discover cell lines that can significantly enhance the productivity of viral vectors. Its unique gene barcoding system links information on viral vector productivity with the cell lines producing the vectors, allowing for the simultaneous parallel screening of millions of candidate cell lines.The company completed a $55 million Series A financing last year. According to the company's press release, this technology could revolutionize the economics of gene therapy and expand the patient population reached by this treatment model.
24. Mariana Oncology
Mariana (formerly known as Curie Therapeutics) secured a $75 million Series A financing in December 2021, focusing on the development of next-generation precision-delivery radiopharmaceuticals for cancer treatment. Depending on whether the extracellular domain of tumor cells has a clearly defined structure, Mariana can utilize either a macrocyclic peptide-based or a proprietary non-peptide platform for drug development.By combining radionuclides with Mariana's proprietary ligands, the radiopharmaceuticals developed by Mariana Oncology can precisely target tumors, distribute evenly within the tumor, carry a high payload, and be rapidly cleared from the circulatory system while maintaining excellent safety.Thus, it has the potential to become a "best-in-class" precision cancer therapy.
{replyUser1}Reply{replyUser2}：{content}